Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06630845 · ClinicalTrials.gov registry record · NA
Comparison of Whole Body DWI to FDG PET
A NA study of Metastatic Cancer, sponsored by University of California, San Francisco.
- Recruiting
- Registry status
- NA
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT06630845: Recruiting NA study of Metastatic Cancer, sponsored by University of California, San Francisco.
NCT06630845 is a NA study of Metastatic Cancer that is actively recruiting participants, run by University of California, San Francisco. The registered enrollment target is 30 participants, below the 444-participant average among 109 other Metastatic Cancer trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06630845, a NA study of Metastatic Cancer, is actively recruiting participants, sponsored by University of California, San Francisco.
- RECRUITING
- Registry status
- NA
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a single arm prospective trial that evaluates whole body diffusion weight imaging (DWI) compared to 18F-fludeoxyglucose (FDG) Positron Emission Tomography with Magnetic resonance imaging (PET/MRI) in participants with known metastatic cancer.
Primary Outcome
The overall proportion of lesions that will be characterized as positive on whole body (WB) diffusion weight imaging (DWI) and FDG PET.
Conditions Studied
Interventions
- DRUG Fluorodeoxyglucose F18
- PROCEDURE Positron Emission Tomography combined with Magnetic resonance imaging (PET/MRI)
- PROCEDURE Whole Body Magnetic Resonance Imaging with Diffusion-Weighted Imaging (WB-MRI-DWI)
- DEVICE General Electric (GE) SIGNA PET/MR
Study Locations (1)
California
- University of California, San Francisco - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2025-02-06 |
| Est. Completion | 2029-10-31 |
| Phase | NA |
What NCT06630845 shows while recruiting
NCT06630845 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 444-participant average among 109 other Metastatic Cancer trials with a reported enrollment target (93% lower).
The record links to 1 condition, with Metastatic Cancer appearing as the primary indexed condition, and to 4 interventions - of which Fluorodeoxyglucose F18 is the first listed.
NCT06630845 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT06630845 about?
NCT06630845 is a clinical study titled "Comparison of Whole Body DWI to FDG PET". This is a single arm prospective trial that evaluates whole body diffusion weight imaging (DWI) compared to 18F-fludeoxyglucose (FDG) Positron Emission Tomography with Magnetic resonance imaging (PET/MRI) in participants with known metastatic cancer.
What is the current status of trial NCT06630845?
This trial is currently recruiting. It is a NA study. The enrollment target is 30 participants. The study started on 2025-02-06. Estimated completion is 2029-10-31.
What conditions does trial NCT06630845 study?
This clinical trial studies the following conditions: Metastatic Cancer.
What interventions are being tested in trial NCT06630845?
The interventions under investigation include: Fluorodeoxyglucose F18 (DRUG), Positron Emission Tomography combined with Magnetic resonance imaging (PET/MRI) (PROCEDURE), Whole Body Magnetic Resonance Imaging with Diffusion-Weighted Imaging (WB-MRI-DWI) (PROCEDURE), General Electric (GE) SIGNA PET/MR (DEVICE).
Who is sponsoring clinical trial NCT06630845?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06630845 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06630845's enrollment target sits among peer trials
30 80th of 109 higher than 27 of 109 other Metastatic Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Metastatic Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Longitudinal Screening for Financial Hardship to Improve Outcomes in Patients With Advanced Cancer
RECRUITING · NA
-
PROGRESS: Precision Oncology Using Genomic Reflexive Evaluations for Study Selection and Survival
RECRUITING · NA
-
A Study of the ApricityCare Program for Early Detection and Management of Treatment-Related Adverse Events in Patients With Cancer
RECRUITING · NA
-
Palliative Spatially Fractionated (GRID) Radiotherapy Using Intensity Modulated Proton Therapy
RECRUITING · NA
-
COBRA: Cancer, Older Adults, Balance and Resistance Activities
RECRUITING · NA
-
Copper Cu 64 Anti-CEA Monoclonal Antibody M5A PET in Diagnosing Patients With CEA Positive Cancer
ACTIVE NOT RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI